AbbVie engages in pharmaceutical research and development to provide innovative solutions for patients.

AbbVie

Solbosch provides a variety of medical and paramedical specialties. It is equipped with a viral air purifier.

Solbosch

Nobias Therapeutics is a clinical-stage company developing novel small-molecule therapeutics for rare diseases, focusing initially on pediatric indications and expanding to adults and non-rare indications. This description is self-described.

Nobias Therapeutics

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

Metric
Company Name	AbbVie	Solbosch	Nobias Therapeutics	RVL Pharmaceuticals plc
Symbol				RVLP
MSH ID	AR:COM:ABBVIE	BE:SOLBOSCH	COM:NOBIASTX	COM:RVLPHARMA
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services	Healthcare
Industry	Pharmaceuticals	Healthcare	Biotechnology	Biotechnology
Country	AR	BE	US	US
Stage			Series A
Employee Count				125
Website	abbvie.com.ar	solbosch.be	nobiastx.com	rvlpharma.com
LinkedIn		le-solbosch	nobias-therapeutics	rvl-pharmaceuticals-inc
Founders

Metric
Market Cap		3.14M
Enterprise Value
Monthly Web Traffic	270	1.19K
Web Traffic Growth	-0.35	-0.82
Valuation
Raised Capital	3.75M

Metric
Revenue				49.72M
Revenue (LTM)
Revenue (NTM)
Gross Profit				40.27M
EBITDA				-36.19M
Operating Income				-45.68M
Net Income				-51.69M
EPS				-0.58
Diluted EPS				-0.58
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				0.75
Operating Profit Margin				-1.56
EBITDA Margin				-0.73
Net Profit Margin				-1.85
Return on Equity				-1.55
Return on Assets				-0.80
Return on Capital Employed				-3.38

COM

AR:COM:ABBVIE

AbbVie

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				-0.04
P/B Ratio				0.17
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				0.09
EV Multiple				0.99

Metric
Days Sales Outstanding				19.10
Days Payables Outstanding				98.98
Days Inventory Outstanding				53.05
Operating Cycle				72.15
Cash Conversion Cycle				-26.83
Asset Turnover				0.43

Metric
Operating Cash Flow				-37.81M
Free Cash Flow				-38.56M
Cash Flow to Debt				-0.76
Operating Cash Flow/Sales				-1.20
Free Cash Flow Yield				-15.11

Metric
Cash & Equivalents				44.54M
Accounts Receivable				-898K
Inventory				784K
Goodwill				55.85M
Debt to Capitalization				0.78
Debt to Assets				0.68
Current Ratio				0.38
Quick Ratio				0.31

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue				0.06
R&D to Revenue				0.08
SG&A to Revenue